Reversible renal impairment during leukocytosis induced by G-CSF in non-Hodgkin's lymphoma.
Hirokawa
M
M
Lee
M
M
Motegi
M
M
Miura
A B
AB
D000293:Adolescent; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects* / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D007414:Intestinal Neoplasms / Q000097:blood / Q000150:complications* / Q000628:therapy; D007674:Kidney Diseases / Q000139:chemically induced*; D007964:Leukocytosis / Q000139:chemically induced* / Q000150:complications; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000150:complications* / Q000628:therapy; D008297:Male; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D014748:Vinca Alkaloids / Q000008:administration & dosage / Q000009:adverse effects
D000903:Antibiotics, Antineoplastic; D007155:Immunologic Factors; D011994:Recombinant Proteins; D014748:Vinca Alkaloids; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D000069585:Filgrastim